Facebook link Linked In link You Tube link
  • Education2015

    Share Your Science

    Attendees from around the globe share their research and advance their careers. See their work

  • Industry2015

    Industry Partnership

    FOCIS provides a plethora of opportunities for industry to interact with immunology experts from around the world. Learn more.

  • 2016AdvCourseSunglasses

    2017 Advanced Course Registration Now Open!

    The ever-popular Advanced Course is headed back to Scottsdale, AZ from February 19-22. Register now!

  • Science Immunology Homepage Slider

    New Journal Showcasing Innovative Advances

    FOCIS members receive complimentary access to the journal. Read the current issue.

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 17th Annual Meeting in Chicago, Illinois!  

News & Information

New Chilean Workshop Announced - FOCIS Goes South

We are glad to invite you to the first FOCIS course to be held in Santiago de Chile: "FOCIS goes South: Advances in Translational and Clinical Immunology" hosted by the Millennium Institute on Immunology and Immunotherapy (www.imii.cl), a recently incorporated FOCIS Excellence Center.

This workshop will be held this upcoming year 2017 on May 15-17th with excellent international and regional speakers.

The workshop will focus on immunological mechanisms and treatments in autoimmunity, cancer, inflammation and infectious diseases. This is a great opportunity for establishing and expanding collaborative networks in South America.

Just Announced! Clinical Immunology Trainee Award

Together with FOCIS, Clinical Immunology has established the Clinical Immunology Trainee Award for a colleague in training (student or fellow) to be selected among those who submit abstracts to the FOCIS Annual Meeting.

The recipient of the Clinical Immunology Trainee Award will receive complimentary registration to attend FOCIS 2017, up to four nights of accommodation at Hilton Chicago, and reimbursement for coach airfare and ground transportation expenses. The recipient will be recognized at a session during FOCIS 2017. This award cannot be combined with any other FOCIS 2017 travel awards.



All Articles...


 FOCIS 2017 Sponsors

 Graphic of FOCIS 2017 Supporters


ePub header 2016

December 22, 2016
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Early Dysregulation Leads to Autoimmune Disease in Adults

Antibodies against self-proteins can be present for years to decades before the development of overt autoimmune disease, suggesting that a loss of tolerance may exist amongst circulating immune cells that precedes tissue injury. The authors studied autoimmunity in a mouse model of Sjögren’s disease in order to identify the type and timing of immune dysregulation that made these mice susceptible to inflammatory disease later in life.


  Reviewed by Rachael A. Clark, MD, PhD, Brigham and Women's Hospital


Developments in Basic Immunology and Novel Therapies

circlearrow2 Exploiting Metabolism in T cells to Treat Immune Mediated Disease

Over the previous decade, several groups have elucidated details of metabolic pathways that drive survival, growth and differentiation in T lymphocytes1,2. T cells differ in their utilization of metabolic pathways and therefore energy sources depending on the specifics of T cell subset and state of activation. The bio-energetics needs of a resting naïve lymphocyte are different from one that is rapidly expanding and differentiating or actively regulating immune responses. It is now clear that this influences the quality and immune responses.


  Submitted by Jonathan S. Maltzman, MD, PhD, FAST, Veterans Affairs Palo Alto Health Care System and Stanford University


Selected Recent Clinical Trial Results

circlearrow2 Activity of Secukinumab, an Anti-IL-17A Antibody, on Brain Lesions in RRMS: Results From a Randomized, Proof-Of-Concept Study

Clinical Trial: Havrdova E, Belova A, Goloborodko A, et al. J Neurol (May 2016) 263:1287-1295

Disease: relapsing remitting multiple sclerosis (RRMS)

Intervention: secukinumab 10 mg/kg or placebo. Secukinumab is a human monoclonal antibody that binds to IL-17A



  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute